Partnerships

Industry Partnerships

Bristol-Myers Squibb

Bristol Myers Squibb, Inc.

We have a clinical trial collaboration agreement with Bristol Myers Squibb for our bacterial consortia drug candidate for Immune-Oncology VE800.

Biomedical Advanced Research and Development Agency (BARDA)

Vedanta has been awarded a development grant from BARDA to advance VE303 through clinical and regulatory development for CDI.

CARB-X

Vedanta has been awarded two research grants from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of VE303, the Company’s product candidate for the treatment of high-risk C. difficile infection (CDI) and VE707, Vedanta’s preclinical discovery program for the prevention of infection and recurrence of several MDROs, including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE).

JSR Corporation

We have a collaboration agreement with JSR to develop next-generation manufacturing techniques for live biotherapeutic products.

Academic Collaborations

Academic Collaborations

Leiden University Medical Center

We have entered into a clinical translational medicine collaboration with Leiden University Medical Center that focuses on collection of samples from healthy donors as well as clinical data and/or interventional studies of fecal transplantation in a variety of indications.

Centre hospitalier de l'Université de Montréal

We have entered into a translational collaboration with CHUM focused on understanding the microbiome of cancer patients being treated with checkpoint inhibitors.

NYU Langone Medical Center

We have entered into a translational collaboration with the NYU Langone Medical Center focused on developing novel microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.

Hôpital Raymond Poincaré

We have entered into a translational collaboration with Hôpital Raymond Poincaré focused on the development of microbiome-based therapeutics for multi-drug resistant organisms.

Vall d'Hebron Institute of Oncology

We have entered into a translational medicine collaboration with VHIO to understand how the microbiome of cancer patients influences responses to immune checkpoint inhibitors.

The Leading Platform for Development of Bacterial Consortia Therapeutics

Our discovery platform enables identification of bacterial consortia with drug-like properties and their manufacture to GMP standards.

How Our Proprietary Discovery Platform Works